Abirapro 250mg - Anticancer drugs | view uses, side effects and price | MHP

DESCRIPTION
Abirapro 250mg is belongs to anti neoplastic drugs which will work by Diminish the androgen production in the body. Androgen is a male hormone which balances the cancer cell in prostate glands.

Normaly this tablet is taken by combination with prednisolone, a steroid which decreases the liability of side effects produced by Abiraterone.

PHARMACOKINETICS
ABSORPTION
Time to median plasma concentration of tablet Abirapro takes 12 hours.
DISTRIBUTION
Maximum bound to the human plasma protein like albumin and alpha-1 acid glycoprotein.
METABOLISM
The main two metabolites of Abiraterone in human plasma are Abiraterone sulphate and N-oxide Abiraterone sulphate.
ELIMINATION
Terminal half life of tablet Abirapro is 12 ± 5 hours. The drug mainly excreted in 88% feces and 5% in urine.

PRODUCT DETAILS

Brand : Abirapro
Ingredients : Abiraterone acetate
Strength : 250mg
Manufactured : Glenmark Pharmaceuticals
Package : 120 Tablets

DOSAGE MANAGEMENT
The usual dose of Abirapro 250mg tablet is endorsed as 4 tablets orally once daily The drug Abirapro given with 5mg prednisolone twice daily in empty stomach. Abirapro Tablets administrated on an empty stomach. No food should be consumed for at least 2 hours before and at least 1 hour after the dose of Abirapro Tablets is taken. Abirapro should be swallowed whole with water. Do not crush or chew the tablets.

OVERDOSAGE
Abirapro has no specific antitoxin, If overdose occurs stop the drug and provide general supportive measures such as monitoring arrhythmias and cardiac failure and assess liver function.

COMMON EFFECTS
Fatigue, Arthralgia, Hypertension, Nausea, edema, Hypokalemia, Diarrhea, vomiting, Cough, headache, Glucocorticoid deficiency, Mineral corticoid deficiency Hepatotoxicity Hypertension, Decrease in ka level Adrenocortical insufficiency

DRUG INTERACTION
Abirapro 250mg interaction with dextromethorphan will increases the Cmax and AUC of dextromethorphan Abirapro interaction with strong CYP3A inhibitors or inducers , use combination with caution because pharmacokinetics is not evaluated.